抗体

小鼠单克隆抗体抗人类DNMT3B

MBS120171

0.1毫克

345美元

单克隆

小鼠

未共轭

2280C3a

免疫印迹, 免疫细胞化学, 流式细胞仪, 流式细胞仪

抗体

小鼠单克隆抗体抗人类DNMT3B

DNMT3B

Homo sapiens DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B), transcript variant 2, mRNA; ICF; M.HsaIIIB

Homo sapiens DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B), transcript variant 2, mRNA; DNA (cytosine-5)-methyltransferase 3B; DNA (cytosine-5)-methyltransferase 3B; DNA (cytosine-5)-methyltransferase 3B; DNA MTase HsaIIIB; DNA methyltransferase HsaIIIB; DNA (cytosine-5-)-methyltransferase 3 beta; DNA methyltransferase HsaIIIB; DNA MTase HsaIIIB; M.HsaIIIB

DNMT3B

DNMT3B;DNMT3B;ICF;ICF1;M.HsaIIIB

DNM3B_HUMAN

单克隆

IgG2b

2280C3a

小鼠

人类

4293

100微克/毫升(1.0毫升)

Dot Blot (DB), Immunocytochemistry (ICC), Western Blot (WB), Flow Cytometry (FC/FACS)

Preparation: This antibody was purified using protein G column chromatography from culture supernatant of hybridoma cultured in a medium containing bovine IgG-depleted (approximately 95%) fetal bovine serum.

Sterility: Filtered through a 0.22 um membrane.

CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase which is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes primarily to the nucleus and its expression is developmentally regulated. Mutations in this gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Six alternatively spliced transcript variants have been described. The full length sequences of variants 4 and 5 have not been determined. [NCBI Entrez Gene Summary]

28559060

NP_787044.1

NM_175848

81,311 Da

Cysteine And Methionine Metabolism Pathway (104488); Cysteine And Methionine Metabolism Pathway (103421); DNA Methylation Pathway (1127677); Epigenetic Regulation Of Gene Expression Pathway (1127671); Gene Expression Pathway (105937); Metabolic Pathways (132956); Methionine Degradation Pathway (413353); Methionine Degradation Pathway (468228); MicroRNAs In Cancer Pathway (852705); MicroRNAs In Cancer Pathway (852928)

CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase which is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes primarily to the nucleus and its expression is developmentally regulated. Mutations in this gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Eight alternatively spliced transcript variants have been described. The full length sequences of variants 4 and 5 have not been determined. [provided by RefSeq, May 2011]

DNMT3B: a ubiquitous DNA methyltransferase required for genome wide de novo methylation and essential for development. DNA methylation is coordinated with methylation of histones. Numerous cancer cell lines and primary acute leukemias express aberrant DNMT3B transcripts, especially DNMT3B7. Transfection of DNMT3B7 into 293 cells alters the pattern of genes expressed in the transfected cells. Can interact with DNMT1, which might be a co-operative event during DNA methylation. Methylates CpG sites at a rate slower than DNMT3A and much slower than DNMT1. Interacts with SUV39H1, SETDB1, SUMO1 and UBE2I9. Interacts with DNMT1 and DNMT3A. Mutations in DNMT3B have been shown to cause immunodeficiency-centromeric instability-facial anomalies syndrome (ICF). Six alternatively spliced isoforms of the human protein have been reported. Isoform 1 is expressed in all tissues except brain, skeletal muscle and PBMC, 3 is ubiquitous, 4 is expressed in all tissues except brain, skeletal muscle, lung and prostate and 5 is detectable only in testis and at very low level in brain and prostate. Isoforms 4 and 5 are probably not enzymatically active due to the deletion of two conserved methyltransferase motifs. Protein type: EC 2.1.1.37; Cell development/differentiation; Methyltransferase, DNA; Methyltransferase; Amino Acid Metabolism - cysteine and methionine. Chromosomal Location of Human Ortholog: 20q11.2. Cellular Component: nucleoplasm; intracellular membrane-bound organelle; cytoplasm; nuclear heterochromatin; nucleus. Molecular Function: DNA (cytosine-5-)-methyltransferase activity; protein binding; DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates; unmethylated CpG binding; metal ion binding; transcription corepressor activity; DNA-methyltransferase activity. Biological Process: response to drug; negative regulation of histone H3-K9 methylation; genetic imprinting; S-adenosylhomocysteine metabolic process; positive regulation of histone H3-K4 methylation; negative regulation of transcription from RNA polymerase II promoter; regulation of gene expression, epigenetic; cytosine methylation within a CG sequence; protein complex localization; methylation-dependent chromatin silencing; negative regulation of gene expression, epigenetic; DNA methylation; S-adenosylmethioninamine metabolic process; gene expression; response to ionizing radiation; positive regulation of neuron differentiation; DNA methylation on cytosine. Disease: Immunodeficiency-centromeric Instability-facial Anomalies Syndrome 1

0.1毫克

345美元